BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Neurome, Inc. Announces Broadened Collaboration With Wyeth (WYE)


11/21/2005 10:24:25 AM

LA JOLLA, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Neurome today announced the expansion of its discovery research collaboration with Wyeth (NYSE: WYE - News), which is currently focused on the investigation of certain aspects of CNS disease using Neurome's proprietary discovery technologies and expertise in quantitative neuropathology. Under the terms of the expanded research collaboration, Neurome will evaluate the effectiveness of possible drug candidates as part of intervention studies in an animal model of neurodegenerative disease. Financial terms of the agreement were not disclosed.

"Our partnership with Wyeth has been highly productive," commented Floyd E. Bloom, M.D., Chief Executive Officer, Chief Scientific Officer and Chairman of the Board of Neurome. "We look forward to increasing our efforts with Wyeth to include the evaluation of potential therapeutic compounds to determine their effectiveness against neurodegenerative illnesses."

"The technology we have developed at Neurome is ideally suited to the comprehensive evaluation of drug candidates in preclinical animal models of disease," said Warren G. Young, Ph.D., President and Chief Operating Officer of Neurome. "We are delighted that Wyeth has decided to expand the scope of its work with us to include these studies, which we believe will provide highly relevant data, useful in determining successful reversal of disease pathology."

About Neurome

Neurome, Inc. is a discovery stage biotechnology company that seeks therapeutic solutions to human neurodegenerative diseases. The company focuses its efforts on Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) -- usually fatal neurodegenerative disorders that are currently untreatable and share characteristics which make them particularly amenable to Neurome's expertise and technologies. Neurome is also engaged in the research and development of novel delivery systems for targeted mucosal vaccines.

Since its founding in 2000, Neurome has developed and optimized proprietary technologies to reveal and quantify gene expression patterns and the resultant morphological details of brain structures in normal and pathological brains with an unprecedented level of sensitivity, specificity and resolution. Neurome's unique technologies to measure and assess neurodegenerative processes at work -- at the molecular, cellular and macroscopic levels -- are ideally suited to identify the earliest evidence of pathology in models of human diseases of the Central Nervous System, as well as to evaluate the comparative effectiveness of pharmaceutical candidates for intervention. The company dedicates these technologies to discovery and development of drugs to provide effective treatments for diseases characterized by neurodegeneration. Detailed information on the Neurome technologies and the scientific and medical challenges of human neurodegenerative disorders are available at Neurome's website: www.neurome.com.

Source: Neurome, Inc.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->